First report of medulloblastoma in a patient with MUTYH-associated polyposis.
MUTYH
medulloblastoma
mutational signature
oncogenetics
whole exome sequencing
Journal
Neuropathology and applied neurobiology
ISSN: 1365-2990
Titre abrégé: Neuropathol Appl Neurobiol
Pays: England
ID NLM: 7609829
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
11
07
2023
received:
13
12
2022
accepted:
22
07
2023
medline:
31
8
2023
pubmed:
1
8
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
The mutY DNA glycosylase encoded by the MUTYH gene prevents G:C → T:A transversions through the base excision repair DNA repair system. Germline biallelic pathogenic variants in MUTYH cause an adenomatous polyposis called MUTYH-associated polyposis (MAP), an autosomal recessive disease (OMIM: 608456), with an increased risk of colorectal cancer. Digestive lesions in this context show an excess of G:C → T:A transversions, individualising a specific mutational signature associated with MUTYH deficiency called signature SBS36. Predisposition to other tumours in patients with germline biallelic pathogenic variants in MUTYH is suspected but remains unclear. We report the first case of medulloblastoma in a patient with MAP, carrying the homozygous pathogenic variant c.1227_1228dup, p.(Glu410Glyfs*43) in MUTYH. Whole exome sequencing was performed on the medulloblastoma to enlighten single nucleotide variants of interest, microsatellite status and mutational signature. The objective was to determine the involvement of MUTYH deficiency in the oncogenesis of this medulloblastoma. The medulloblastoma has the mutational signature SBS36 and driver pathogenic variants in CTNNB1, PTCH1 and KDM6A corresponding to G:C → T:A transversions, suggesting a role of MUTYH deficiency in oncogenesis. Therefore, medulloblastoma could be a rare manifestation associated with germline biallelic pathogenic variants in MUTYH.
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12929Informations de copyright
© 2023 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.
Références
Kairupan C, Scott RJ. Base excision repair and the role of MUTYH. Hered Cancer Clin Pract. 2007;5(4):199-209. doi:10.1186/1897-4287-5-4-199
al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C-->T:a mutations in colorectal tumors. Nat Genet. 2002;30(2):227-232. doi:10.1038/ng828
Colas C, Bonadona V, Baert-Desurmont S, et al. MUTYH-associated polyposis: review and update of the French recommendations established in 2012 under the auspices of the National Cancer institute (INCa). Eur J Med Genet. 2020;63(12):104078. doi:10.1016/j.ejmg.2020.104078
Sutcliffe EG, Bartenbaker Thompson A, Stettner AR, et al. Multi-gene panel testing confirms phenotypic variability in MUTYH-associated polyposis. Fam Cancer. 2019;18(2):203-209. doi:10.1007/s10689-018-00116-2
Villy MC, Masliah-Planchon J, Buecher B, et al. Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum. Eur J Med Genet. 2022;65(1):104385. doi:10.1016/j.ejmg.2021.104385
Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology. 2009;137(6):1976-1985.e10. doi:10.1053/j.gastro.2009.08.052
Win AK, Reece JC, Dowty JG, et al. Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH [published correction appears in Int J cancer. 2017 Dec 15;141(12):E7]. Int J Cancer. 2016;139(7):1557-1563. doi:10.1002/ijc.30197
Juraschka K, Taylor MD. Medulloblastoma in the age of molecular subgroups: a review. J Neurosurg Pediatr. 2019;24(4):353-363. doi:10.3171/2019.5.PEDS18381
Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer [published correction appears in nature. 2013 Oct 10;502(7470):258. Imielinsk, Marcin [corrected to Imielinski, Marcin]]. Nature. 2013;500(7463):415-421. doi:10.1038/nature12477
Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018;19(6):785-798. doi:10.1016/S1470-2045(18)30242-0
Shinde J, Bayard Q, Imbeaud S, et al. Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer. Bioinformatics. 2018;34(19):3380-3381. doi:10.1093/bioinformatics/bty388
Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941-D947. doi:10.1093/nar/gky1015
Northcott PA, Shih DJ, Remke M, et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 2012;123(4):615-626. doi:10.1007/s00401-011-0899-7
Kuschel LP, Hench J, Frank S, et al. Robust methylation-based classification of brain tumours using nanopore sequencing. Neuropathol Appl Neurobiol. 2023;49(1):e12856. doi:10.1111/nan.12856
Helgager J, Pytel P, Vasudevaraja V, et al. WNT-activated Medulloblastomas with hybrid molecular subtypes. JCO Precis Oncol. 2020;4(4):348-354. doi:10.1200/PO.19.00332
Iorgulescu JB, Van Ziffle J, Stevers M, et al. Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathol. 2018;135(4):635-638. doi:10.1007/s00401-018-1819-x
Northcott PA, Buchhalter I, Morrissy AS, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017;547(7663):311-317. doi:10.1038/nature22973
Viel A, Bruselles A, Meccia E, et al. A specific mutational signature associated with DNA 8-Oxoguanine persistence in MUTYH-defective colorectal cancer. EBioMedicine. 2017;20:39-49. doi:10.1016/j.ebiom.2017.04.022
Turcot J, Després JP, St. Pierre F. Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum. 1959;2(5):465-468. doi:10.1007/BF02616938
Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med. 1995;332(13):839-847. doi:10.1056/NEJM199503303321302
Aronson M, Colas C, Shuen A, et al. Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. J Med Genet. 2022;59(4):318-327. doi:10.1136/jmedgenet-2020-107627
Yen T, Stanich PP, Axell L, Patel SG. APC-Associated Polyposis Conditions. In: Adam MP, Everman DB, Mirzaa GM, et al., eds. GeneReviews®. University of Washington, Seattle; 1998.
Kline CN, Joseph NM, Grenert JP, et al. Inactivating MUTYH germline mutations in pediatric patients with high-grade midline gliomas. Neuro Oncol. 2016;18(5):752-753. doi:10.1093/neuonc/now013
Bedics G, Kotmayer L, Zajta E, et al. Germline MUTYH mutations and high-grade gliomas: novel evidence for a potential association. Genes Chromosomes Cancer. 2022;61(10):622-628. doi:10.1002/gcc.23054
Zhang J, Walsh MF, Wu G, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336-2346. doi:10.1056/NEJMoa1508054